Erythema elevatum et diutinum, multiple sclerosis and interferon beta

GIL, Marc Jacques, et al.

DOI : 10.1159/000078596
PMID : 15237277

Available at:
http://archive-ouverte.unige.ch/unige:44630

Disclaimer: layout of this document may differ from the published version.
A 42-year-old woman was diagnosed as having multiple sclerosis based on a complex status epilepticus, a pathologic MRI with multiple lesions in the white matter, oligoclonal immunoglobulin in the cerebrospinal fluid and pathologic visual-evoked cerebral potentials. She was treated with carbamazepine and Rebif® (interferon β1a, Serono, Geneva, Switzerland). One year later, she developed arthralgia of the hands, knees and ankles as well as a painful heel. Despite discontinuing interferon, the arthralgias persisted and skin lesions appeared.

At presentation, she had swollen proximal interphalangeal joints of the left second and third fingers and a swollen insertion of the left index finger that exhibited a dermal infiltrate upon diascopy. A skin biopsy showed a dermal perivascular and interstitial mixed neutrophilic and mononuclear cell infiltrate. Many leukocytes exhibited signs of apoptosis. Extravascular erythrocytes were identified. The microvascular endothelium was turgescent, but no fibrinoid necrosis of the vessel walls was detected. The superficial dermis exhibited moderate fibrosis. A diagnosis of erythema elevatum et diutinum (EED) was made. ESR was 28 mm in the first hour (normal!)
in a patient with multiple sclerosis has been reported [25].

Despite normal glucose-6-phosphate dehydrogenase levels, anemia (94 g/l) without signs of hemolysis developed. Dapsone was discontinued, and the skin nodules and the arthralgias recurred. Dapsone was reintroduced at 100 mg/day and well tolerated. The joint pain and the skin nodules disappeared again. Six months later, Dapsone was stopped without cutaneous or articular relapse. An alternative treatment for multiple sclerosis was initiated.

EED is a form of neutrophil-rich vasculitis [1] often lumped together with Sweet syndrome, pyoderma gangrenosum, rheumatoid neutrophilic dermatosis, neutrophilic eccrine hidradenitis and Sneddon-Wilkinson subcorneal pustular dermatosis under the term of neutrophilic dermatoses. Behcet’s disease is also associated with neutrophil-rich infiltrates of the skin. Aside from IgA paraproteinemia with or without myeloma, myelodysplastic and myeloproliferative diseases, lymphoma and POEMS syndrome, EED is associated with arthralgia and a number of autoimmune and inflammatory disorders such as rheumatoid arthritis [1], ulcerative colitis [2], Crohn’s disease [3], relapsing polychondritis [4], type 1 diabetes [5], Wegener’s granulomatosis [6], celiac disease [7], myasthenia gravis [8], hyper-IgD syndrome [9] and HIV infection [10]. We found no association of multiple sclerosis with EED. Pyoderma gangrenosum in a patient with ulcerative colitis and multiple sclerosis [11] and a patient with subcorneal pustular dermatosis and multiple sclerosis [12] have been reported. CNS involvement of Behcet’s disease can mimic multiple sclerosis [13]. Interferon β could have precipitated EED, but we found no cases of histologically documented vasculitis or neutrophilic dermatosis associated with interferon β therapy. Skin ulcerations or vasculitis-like lesions observed after interferon β injection appear to be due to vascular thrombosis [14]. Webster et al. [15] reported 1 patient with multiple sclerosis undergoing treatment with interferon β and developing a pustular flare of her usually mild psoriasis. Treatment with interferon α which shares the receptor with interferon β has been associated with vasculitis including histologically documented leukocytoclastic vasculitis although leukocytoclastic vasculitis may rather be due to the underlying chronic hepatitis C in that case [16]. Other neutrophilic dermatoses such as pyoderma gangrenosum [17], ‘granulomatous and supplicative dermatitis’ [18] but not EED have been diagnosed during interferon α treatment. The relation between interferon α and neutrophilic dermatoses, however, is not clear because cases of Sweet’s syndrome [19, 20] and pyoderma gangrenosum [21, 22] have regressed under treatment with this cytokine. Similarly, the relation between arthritis and interferon β treatment is not clear. While it appeared beneficial for rheumatoid arthritis [23, 24], appearance of arthritis during treatment with interferon β in a patient with multiple sclerosis has been reported [25].
References


Conrad Hauser, Unité d’Allergologie
Service d’Immunologie et d’Allergologie
Hôpitaux Universitaires de Genève, 24, rue Micheli-du-Crest
CH–1211 Geneva 14 (Switzerland)
Tel. +41 22 372 9381, Fax +41 22 372 9416
E-Mail Conrad.Hauser@medecine.unige.ch